Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 37,700 shares, a decrease of 82.9% from the June 30th total of 220,500 shares. Approximately 7.8% of the shares of the company are short sold. Based on an average daily trading volume, of 352,900 shares, the days-to-cover ratio is presently 0.1 days.
Institutional Investors Weigh In On Bluejay Diagnostics
An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 24,230 shares of the company’s stock, valued at approximately $30,000. Armistice Capital LLC owned about 1.95% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 18.47% of the company’s stock.
Bluejay Diagnostics Price Performance
NASDAQ BJDX traded down $0.01 during trading hours on Thursday, reaching $0.55. The company’s stock had a trading volume of 77,963 shares, compared to its average volume of 166,396. The firm has a market capitalization of $187,340.00, a price-to-earnings ratio of -0.01 and a beta of 0.82. Bluejay Diagnostics has a 1-year low of $0.51 and a 1-year high of $89.12. The company’s 50-day moving average is $2.54 and its two-hundred day moving average is $4.81.
Bluejay Diagnostics Company Profile
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Featured Stories
- Five stocks we like better than Bluejay Diagnostics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Qualcomm Stock Could Be On The Verge of an Impressive Rally
- Election Stocks: How Elections Affect the Stock Market
- Conviction Firms For Chipotle Stock’s 25% Share Price Increase
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.